Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop, often spreading to distant areas.
Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of melanoma. Therefore, the discovery of markers to assess the malignant potential of melanoma more accurately may be necessary to develop appropriate treatments.
‘Cross talk’ between cancer cells and surrounding stromal cells is believed to orchestrate cancer progression through a variety of mechanisms. Cancer-associated fibroblasts (CAFs) – key factors in the tumor microenvironment – in particular have been implicated in cancer cell progression. It has also been reported that exosomes, a type of small vesicles, produced by CAFs play an important role in cancer progression.
A research group led by Naho Fujii and Hisashi Motomura from Osaka Metropolitan University Graduate School of Medicine in Japan investigated the effect of CAF-derived exosomes on the growth of malignant melanoma cells.
The group found that the transmembrane proteins CD9 and CD63 were mainly present on CAF-derived exosomes, and that among the exosomes, the CD9-positive ones inhibited the growth of malignant melanoma cells.
“As a plastic surgeon, usually I provide surgical treatment for skin cancer, but I have wanted to study other treatment methods for a long time,” Fujii said.
“This study suggests that CD9-positive exosomes inhibit the growth of malignant melanoma, so CD9-positive exosomes may be a useful marker to evaluate the malignant grade of melanoma. We expect further research will lead to the development of new treatments in that line.”
Last December, ImaginAb launched a clinical trial to look at the early detection of malignant melanoma.
Partnering 2030: The Biotech Perspective 2023
